Characterization and Progression of Minor Phenomena in Parkinson's Disease (PD)
NCT ID: NCT05240339
Last Updated: 2024-03-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
38 participants
OBSERVATIONAL
2019-04-25
2023-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
1\) To determine the cumulative probability of developing hallucinations or delusions over time in individuals with PD minor phenomena followed for 36 months.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Psychiatric and Cognitive Manifestations of Parkinson's Disease
NCT00360633
Phenomenological and Psychopathological Factors Associated to Hallucinations in Parkinson's Disease
NCT03105401
Role of Retina in Mechanisms of Illusions and Visual Hallucinations Observed in Idiopathic Parkinson's Disease
NCT03454269
Hallucinations in Parkinson's Disease
NCT04592965
The Effect of Rehabilitation Training on Orthostatic Hypotension in Parkinson's Patients
NCT06328335
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
PD participants with minor phenomena
Observation of minor phenomena
observation twice a year over 3 years
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Observation of minor phenomena
observation twice a year over 3 years
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Parkinson's disease minor phenomena
* ≥30 years of age
* Proficient in English
* Willing and able to provide informed consent
Exclusion Criteria
* Current or prior treatment with an antipsychotic medication (regardless of indication)
* Diagnosis of mania with psychotic features, bipolar or related disorder, depression with psychotic features, or a psychotic disorder
* Unable or unwilling to complete study activities
* Any medical or psychiatric comorbidity that, in the opinion of the investigator, would compromise study participation
30 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
ACADIA Pharmaceuticals Inc.
INDUSTRY
University of Rochester
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ruth Schneider, MD
Associate Professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Rochester Medical Center
Rochester, New York, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
STUDY00003440
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.